- $621.36m
- $603.55m
- $116.59m
Gyre Therapeutics' Q2 revenue misses estimates
U.S. STOCKS ON THE MOVE-Delcath Systems, Seagate, Perpetua Resources
U.S. STOCKS ON THE MOVE-Oklo, Uranium stocks, Workday
U.S. STOCKS ON THE MOVE-Intuit, Apple, Gold miners
U.S. STOCKS ON THE MOVE-Tesla, Gold miners, Intuit
Gyre Therapeutics tumbles after equity raise
Brief: Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share
Gyre Therapeutics tumbles after stock offering launch
Brief: Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Gyre Therapeutics Inc expected to post earnings of 3 cents a share - Earnings Preview
Brief: Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications
Brief: Gyre Therapeutics Appoints Ping Zhang To Board Of Directors
Brief: Gyre Therapeutics Entered Into Open Market Sale Agreement, May Offer & Sell Shares Of Common Stock Of Up To $50 Million From Time To Time
Brief: Gyre Therapeutics Reports Third Quarter 2024 And Year-To-Date Financial Results And Provides Business Update
Brief: Gyre Therapeutics announces last patient completed pivotal phase 3 trial evaluating F351 For CHB-associated liver fibrosis
Brief: Songjiang Ma Reports 7.62% Stake In Gyre Therapeutics As Of Sept 6 - SEC Filing
Brief: Ying Luo Reports 8.54% Stake In Gyre Therapeutics As Of September 6- SEC Filing
Brief: Gyre Therapeutics Files For Mixed Shelf Offering For $150 Million - SEC Filing